Navigation Links
Symmetry Medical to Present at UBS Global Life Sciences Conference
Date:9/15/2008

WARSAW, Ind., Sept. 15 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: SMA), a leading independent provider of products to the global orthopedic device industry and other medical markets, announced today that Brian S. Moore, President and Chief Executive Officer, is scheduled to present at the UBS Global Life Sciences Conference at The Grand Hyatt New York in New York City on Thursday, September 25, 2008 at 11:30 a.m. ET.

A live Web cast of the presentation will be available on Symmetry Medical's Web site at http://www.symmetrymedical.com. Presentation slides will be posted on the Web site before the presentation begins. A replay of the Web cast will be available for 60 days after the date of the presentation.

About Symmetry Medical Inc.

Symmetry Medical Inc. is a leading independent provider of implants and related instruments and cases to the orthopedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including arthroscopy, dental, laparoscopy, osteobiologic and endoscopy sectors and provides limited specialized products and services to non-healthcare markets, such as the aerospace market.

Investors/Media: Contact:

The Ruth Group Symmetry Medical Inc.

Nick Laudico/Jason Rando Fred L. Hite

(646) 536-7030/7025 Senior Vice President

nlaudico@theruthgroup.com Chief Financial Officer

jrando@theruthgroup.com<
'/>"/>

SOURCE Symmetry Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Symmetry Medical Extends 10-K Filing Beyond April 14, 2008 Target
2. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. Symmetry Medical Reports Preliminary Fourth Quarter Revenue
4. Symmetry Medical Expands Board of Directors
5. Symmetry Medical Reports Preliminary Third Quarter Revenue
6. Symmetry Medical to Provide Third Quarter 2007 General Business Update on November 7, 2007
7. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
8. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
9. Cardica Receives $1 Million Milestone Payment From Cook Medical for Development of Heart Defect Closure Device
10. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... OXFORD, England , May 22, 2013 ... inhaled, novel drug-only formulation of glycopyrronium bromide designed using ... speciality pharmaceutical company developing a portfolio of inhaled ... 2 clinical study with PSX1002 that will assess its ... range of doses in patients with moderate to severe ...
(Date:5/21/2013)... study led by George Washington University Professor Tianshu ... ice in small droplets is strongly size-dependent, an ... nanoscale. The formation of ice at the nanoscale ... answer also has important implications for climate research ... ice from supercooled water is generally initiated by ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, ... that Genzyme, a Sanofi company and leading biotech company, ... for a multi-use facility in the United States. With ... buildings, this latest order underscores the satisfaction and success ... device improving doorway access control. , “We ...
(Date:5/21/2013)... Md. , May 21, 2013  MacroGenics, ... 1 study of margetuximab (MGAH22), an Fc-modified chimeric ... tumors expressing the HER2 oncoprotein," will be presented ... Society of Clinical Oncology during the Developmental Therapeutics ... 3 at 4:15 – 4:30 PM.  The presentation ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... Funds will extend the National ... Honolulu, HI ... $2.8 million in research funding from the National Cancer Institute (NCI) to continue the National ... years. , , , , ,Since 2002, PHRI has participated in the NLST, a research ...
... Stemedica ... today that it has been granted a license by the State of California,s Food ... Manufacturing License recognizes Stemedica as being compliant with California law and the applicable provisions ... ...
... , ... DeSilva + Phillips, Media Investment Bankers, has ... M&A practice. Formerly CEO of IncumediX and COO/CSO at MediServe Information ... on over 140 transactions, including acquisitions, technology license and partnership deals, ...
Cached Biology Technology:Pacific Health Research Institute Awarded $2.8 Million in Research Funding 2Pacific Health Research Institute Awarded $2.8 Million in Research Funding 3Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells 2Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells 3DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice 2DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice 3
(Date:5/22/2013)... novel technique that can detect molecular variants in chemical ... of the most important, though time-consuming, processes in analytical ... Nature , post-doctoral researcher David Patterson, Professor of ... Center for Free-Electron Laser Science (CFEL) in Hamburg, Germany ... to identify molecular variants apart, and to determine how ...
(Date:5/22/2013)... of potential environmental and human health effects from ... year has led scientists to recommend stronger government ... lithium-ion (Li-ion) battery materials. That,s the conclusion of ... Environmental Science & Technology . , Oladele A. ... have become mainstays for powering everything from smart ...
(Date:5/22/2013)... screening for prostate cancer could become as easy for ... to UC Irvine research published today in the ... more than a decade of work, UC Irvine chemists ... markers for prostate cancer in urine, meaning that the ... and at dramatically lower cost. The same technology could ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... Aware, Inc. (Nasdaq: AWRE ), a leading supplier ... call to discuss the company,s operating results for the first ... Eastern Time. CEO Michael Tzannes and CFO Rick Moberg will ... Thomson and can be accessed on the Investor Relations page ...
... Park, Md. -- DNA sequencing is the next frontier ... and affordable, it is increasingly available to small laboratories. ... faster rate than ever before. However, the computing ... still has some catching up to do. Large ...
... We have the will but do we have the technology? ... being held May 13 to 15, 2009 at McMaster University ... climate change and global warming. Among the guest speakers ... of Canada and former Premier of Manitoba. He will ...
Cached Biology News:Aware, Inc. Announces Q1 '09 Earnings Conference Call 2A genomic CluE for cloud computing 2A genomic CluE for cloud computing 3
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
...
Biology Products: